The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular...
Date First Received: May 30, 2006
Last Updated: May 30, 2006
Verified by: Allergan, May 2006
Clinical Trial Phase: Phase 3 | Start Date: January 2000
Overall Status: Completed
Estimated Enrollment: 560
Brief Summary
Condition Keyword(s):
Intervention(s):
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: brimonidine/timolol fixed combination
Outcome Measures for this Clinical Trial
Primary Measures
- IOP
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes
- Patient requires IOP-lowering drug in both eyes
Exclusion Criteria:
- Uncontrolled medical condition
- Contraindication to beta-adrenoceptor antagonist or brimonidine therapy
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Allergan
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00332436
Study ID Number: 190342-013T
ClinicalTrials.gov Identifier: NCT00332436
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
